OPG/RANKL/RANK pathway as a therapeutic target in cancer

Journal of Thoracic Oncology

Volumn 6, Issue 9, 2011, Pages 1468-1473

  McGrath, Emmet E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Bone disease; Clinical trials; Metastasis; Osteoprotegerin (OPG); Receptor activator of nuclear factor (RANK) cancer; Receptor activator of nuclear factor ligand (RANKL)

Indexed keywords

DENOSUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; DRUG TARGETING; HUMAN; HYPERCALCEMIA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 80052221635     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318229421f     Document Type: Article

References (64)

1. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80: 1588-1594. (Pubitemid 27444031)
2. Fiddler IJ. Melanoma metastasis. Cancer Control 1995;2:398-404.
3. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: Markers and models. Nat Rev Cancer 2005;5:591-602. (Pubitemid 41081385)
4. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancerinduced bone diseases. Cancer Metastasis Rev 2006;25:541-549. (Pubitemid 46071863)
5. Hanada R, Hanada T, Sigl V, et al. RANKL/RANK-beyond bones. J Mol Med 2011;89:647-656.
6. Wittrant Y, Theoleyre S, Chipoy C, et al. RANKL/RANK/OPG: New therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004;1704:49-57. (Pubitemid 39195349)
7. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9(Suppl 1):S1.
8. Fata JE, Kong YY, Li J, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000;103:41-50.
9. Kim NS, Kim HJ, Koo BK, et al. Receptor activator of NF-kappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol 2006;26:1002-1013.
10. Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175-179. (Pubitemid 27507987)
11. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999;96: 3540-3545. (Pubitemid 29168945)
12. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93: 165-176. (Pubitemid 28180851)
13. Khosla S. Minireview: The OPG/RANKL/RANK system. Endocrinology 2001;142:5050-5055. (Pubitemid 33131929)
14. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323.
15. Mizuno A, Amizuka N, Irie K, et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998;247:610-615. (Pubitemid 28418439)
16. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998;12:1260-1268. (Pubitemid 28213402)
17. McGrath EE, Marriott HM, Lawrie A, et al. TNF-related apoptosis inducing ligand (TRAIL) regulates inflammatory neutrophil apoptosis and resolution of inflammation. J Leukoc Biol. 2011 May 11. [Epub ahead of print].
18. McGrath EE. The tumor necrosis factor-related apoptosis inducing ligand and lung cancer: Still following the right TRAIL? J Thorac Oncol 2011;6:983-987.
19. Sobacchi C, Frattini A, Guerrini MM, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007;39:960-962. (Pubitemid 47185178)
20. Crockett JC, Mellis DJ, Scott DI, et al. New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: Focus on the RANK/RANKL axis. Osteoporos Int 2011;22:1-20.
21. Guerrini MM, Sobacchi C, Cassani B, et al. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet 2008;83:64-76. (Pubitemid 351916706)
22. Cundy T, Hegde M, Naot D, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002;11:2119-2127. (Pubitemid 34994000)
23. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;347:175-184. (Pubitemid 34764821)
24. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu Rev Immunol 2002;20:795-823. (Pubitemid 34293440)
25. Mori K, Le Goff B, Charrier C, et al. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: New insights in the prostate cancer bone metastasis process. Bone 2007;40:981-990. (Pubitemid 46386537)
26. Aeschlimann D, Evans BA. The vital osteoclast: How is it regulated? Cell Death Differ 2004;11(Suppl 1):S5-S7. (Pubitemid 39136790)
27. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-649. (Pubitemid 36917505)
28. Takayanagi H, Kim S, Matsuo K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002;416:744-749. (Pubitemid 34429151)
29. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292:490-495. (Pubitemid 38988958)
30. Boyce BF, Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 2007;5:98-104. (Pubitemid 47577320)
31. Huang L, Cheng YY, Chow LT, et al. Tumour cells produce receptor activator of NF-kappaB ligand (RANKL) in skeletal metastases. J Clin Pathol 2002;55:877-878. (Pubitemid 35316262)
32. Jung K, Lein M, von Hosslin K, et al. Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin Chem 2001;47:2061-2063. (Pubitemid 33010733)
33. Jung K, Stephan C, Semjonow A, et al. Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. J Urol 2003;170:2302-2305. (Pubitemid 37413980)
34. Jones DH, Nakashima T, Sanchez OH, et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692-696.
35. Luo JL, Tan W, Ricono JM, et al. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature 2007; 446:690-694. (Pubitemid 46606879)
36. Akatsu T, Murakami T, Ono K, et al. Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy. Bone 1998;23:495-498. (Pubitemid 28529453)
37. Capparelli C, Kostenuik PJ, Morony S, et al. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res 2000;60:783-787. (Pubitemid 30129501)
38. Clohisy DR, Ramnaraine ML, Scully S, et al. Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. J Orthop Res 2000;18:967-976. (Pubitemid 32055768)
39. Croucher PI, Shipman CM, Van Camp B, et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. Cancer 2003; 97:818-824. (Pubitemid 36125818)
40. Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 2003;63:287-289. (Pubitemid 36152481)
41. Yonou H, Kanomata N, Goya M, et al. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res 2003;63:2096-2102. (Pubitemid 36538612)
42. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 2000;6:521-528. (Pubitemid 30305901)
43. Luger NM, Honore P, Sabino MA, et al. Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 2001;61:4038-4047. (Pubitemid 32720968)
44. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63:7883-7890. (Pubitemid 37466723)
45. Sordillo EM, Pearse RN. RANK-Fc: A therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-812. (Pubitemid 36125816)
46. Oyajobi BO, Mundy GR. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: Novel therapeutic targets in myeloma. Cancer 2003;97:813-817. (Pubitemid 36125817)
47. Santini D, Galluzzo S, Zoccoli A, et al. New molecular targets in bone metastases. Cancer Treat Rev 2010;36(Suppl 3):S6-S10.
48. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab 2008;93:2149-2157. (Pubitemid 351831529)
49. Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007;25:4431-4437. (Pubitemid 350013849)
50. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354: 821-831. (Pubitemid 43290920)
51. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone 2008;43:222-229.
52. Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009:1-34.
53. Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008;26:4875-4882.
54. Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361:756-765.
55. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-755.
56. Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol 2010;28:5132-5139.
57. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564-1571.
58. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011;29:1125-1132.
59. Castellano D, Sepulveda JM, Garcia-Escobar I, et al. The role of RANK-ligand inhibition in cancer: The story of denosumab. Oncologist 2011;16:136-145.
60. Weintraub B. Trials define anti-tumor effects of anti-resorptive agentsdagger: Denosumab ahead of zoledronate 2 to 1. BioDrugs 2011;25:135-138.
61. Available at: Www.clinicaltrials.gov. Accessed May 1, 2011.
62. Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010;468:98-102.
63. Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010;468:103-107.
64. Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature 2011;470:548-553.